EDECRIN (ethacrynic acid) by Bausch + Lomb. Approved for loop diuretic [epc]. First approved in 1967.
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
EDECRIN (ethacrynic acid) is a potent loop diuretic approved in 1967 that works by inhibiting sodium and chloride reabsorption in the ascending limb of the loop of Henle. It is used to treat fluid overload conditions including edema associated with congestive heart failure, liver cirrhosis, and renal disease. The drug is administered orally as a tablet and remains a legacy option for patients who may be intolerant to other loop diuretics.
Declining market presence with minimal spending signals a legacy product with limited commercial infrastructure and reduced team investment opportunities.
Loop Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on EDECRIN offers limited career growth due to minimal commercial activity (zero linked job postings) and approaching loss of exclusivity with no active development pipeline. This role is suitable only for professionals seeking experience managing mature, declining products or niche therapeutic areas.
Worked on EDECRIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo